OTC Zantac Recall: Sanofi Heeds To Potential Ranitidine Contaminant

Firm opts for recall "as a precautionary measure due to inconsistencies in preliminary test results of the active ingredient used in the US and Canadian products." Other firms marketing ranitidine in US have started recalls due to concerns about NDMA since potential problem became known in September.

FDABldg64Lab_1200x675

Sanofi is following other firms in recalling ranitidine products available in the US due to the emerging threat of contamination with a nitrosamine impurity, N-nitrosodimethylamine (NDMA), a potential carcinogen.

Sanofi's US office in Bridgewater, NJ, on 18 October said it will conduct a voluntary recall of its Zantac OTC...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Recalls

More from Policy & Regulation